Ogilvy and Healthworld merge to form new agency

Share this article:
Ogilvy Healthcare and Healthworld Communications Group, both WPP companies, have merged to form Ogilvy Healthworld. The agency will provide both consumer and professional marketing services. This merger coincides with the successful win of two new global brand identity accounts for AstraZeneca and Roche.
AstraZeneca has asked the agency to partner with them in the development of a global brand identity for one of their key pipeline products, Galida, which will compete in the Type II Diabetes and Metabolic Syndrome markets. Galida is scheduled for launch in 2007.
The new group was also appointed by the global marketing team at Roche to develop and implement brand strategy and marketing communications for Herceptin, their targeted breast cancer therapy.
Ogilvy Healthworld's client roster includes Pfizer, Johnson & Johnson, GlaxoSmithKline, Wyeth, and AstraZeneca.
Steven Girgenti, who leads Ogilvy Healthworld as global chief executive, said, "Ogilvy Healthworld's unique strategic and creative vision allows a brand challenge to be approached from a 360 degree branding and communications perspective, driving inspired solutions for clients' communication challenges. We are proud to have been appointed by both AstraZeneca and Roche - our aim is not just to generate success for our clients and their brands but to help make the world a healthier place in which to live."
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.